1. Efficacy and safety of epoetin alfa in preoperative anemia in patients undergoing elective cardiac surgery.
- Author
-
Vallés-Torres, Jorge, Puértolas-Ortega, María, Hernando-Vela, Belén, Gallego-Ligorit, Lucía, Marcén-Solanas, Elena, and González-Rodríguez, Victoria Paz
- Abstract
An observational study was conducted to evaluate the efficacy and safety of epoetin alfa in anemic patients undergoing elective cardiac surgery with cardiopulmonary bypass. Perioperative transfusion requirements were also evaluated. The inclusion criteria were patients undergoing elective cardiac surgery with cardiopulmonary bypass with anemia of chronic disease in the preoperative period from January 2021 to December 2023. Anemia of chronic desease was defined as anemia in patients with normal or high ferritin levels (> 100 ng/ml), chronic kidney disease (glomerular filtration rate < 60 ml/min/1.73m2) or conditions that cause inflammation with elevated C-reactive protein levels (> 0.5 mg/dl). Exclusion criteria were urgent surgery, patients with contraindications to epoetin alfa administration and bleeding episode during preoperative period. Patients were evaluated in the anesthesia outpatient department. They received treatment with 500 IU/kg of subcutaneous epoetin alfa weekly for 4 weeks. Informed consent was obtained in cases of off-label use of epoetin alfa. In addition, intravenous iron was administered in patients with ferritin levels below 500 ng/ml. We evaluated the response to epoetin alfa treatment, perioperative transfusion requirements and safety regarding thromboembolic events. Twenty-two patients were included. 40.8 % of the patients were female. Valvular surgery was performed in 17 patients (77.3 %), coronary artery bypass grafting in 2 (9.1 %), combined surgery in 2 (9.1 %) and replacement of part of the aorta in 1 (4.5 %). The mean initial hemoglobin level was 11.1 g/dl (SD ± 0.78) (range 9.7-12). Epoetin alfa was successful in anemia correction In 17 patients (77.3 %). The average increase in hemoglobin levels after epoetin alfa administration was 2.52 g/dl (SD ± 1,70) (range 0.0-5.7). In 4 patients (18.2 %) there was no increase in hemoglobin level or an increase less than 1 g/dl. Twenty patients (90.9 %) had ferritin levels below 500 ng/ml and received intravenous iron therapy. Blood transfusion rate during surgery and hospital stay was 45.5 %. The mean number of units transfused per patient was 0.82 (SD ± 1.22) in the total group and 1.80 (SD ± 1.23) among transfused patients. Compared to all of the patients undergoing elective cardiac surgery, we didn't observe a reduction in transfusion rate or mean number of units transfused per patient. We observed a reduction in the mean number of units transfused among transfused patients. Only one patient had a thromboembolic event that occurred 7 days after surgery in relation with unnoticed paroxysmal atrial fibrillation. Treatment with epoetin alfa in anemic patients undergoing elective cardiac surgery is effective and safe. Response to treatment among patients may differ, so we recommend patient monitoring and an individualized evaluation. Timing of elective surgery is required to achieve anemia correction. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF